Abstract
The current field of biobanking is emerging and expanding very fast with both private and governmental support. We present here based on our own developments recommendations and outlines for standardization in biobanking processes in clinical studies.
The biobank processes are important for the use of samples in developing assays. These measurements are very important in order to document states of health and disease. The data generation and diagnostic indications are beneficial for academic research, commercial healthcare, drug development industry and government regulating agencies.
There is a need for an improved awareness within proteomic and genomic communities regarding the basic concepts of collecting, storing and utilizing clinical samples. In this respect, the aspects of quality control and sample suitability for analysis need to be documented and validated to ensure data integrity and establish contexts for interpretation of results. The current presentation and outline is of major relevance to the proteomic and genomic fields. The standardization aspects of biobanking and the requirements that are needed to run future clinical studies that will benefit the patients where OMICS science will play a major role. A global view of the field is given where best practice and conventional acceptances are presented along with ongoing large-scale biobanking projects.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- SNPs:
-
Single Nucleotide polymorphisms
- IRB:
-
Institutional Review Board
- LIMS:
-
Laboratory Intelligence Management Systems
- BBMRI:
-
The Biobanking and Biomolecular Resources Research Infrastructure
- EC:
-
European Commission
- EU:
-
European Union
References
Apweiler R. Approaching clinical proteomics: current state and future fields of application in fluid proteomics. Clin Chem Lab Med. 2009;47(6):724–44.
Baker M. Biorepositories: building better biobanks. Nature. 2012;486:141–6.
Bozovic A, Kulasingam V. Quantitative mass spectrometry-based assay development and validation: from small molecules to proteins. Clin Biochem. 2013;46:444–55.
Chambers E, Wagrowski-Diehl DM, Lu Z, Mazzeo JR. Systematic and comprehensive strategy for reducing matrix effects in LC/MS/MS analyses. J Chromatogr. 2007;852(1–2):22–34.
Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med. 2010;363:301–4.
Hewitt RE. Biobanking: the foundation of personalized medicine. Curr Opin Oncol. 2011;23(1):112–19.
Khleif SN, Doroshow JH, Hait WN. AACR–FDA–NCI cancer biomarkers collaborative consensus report: advancing the use of biomarkers in cancer drug development. Clin Cancer Res. 2010;16(13):3299–318.
Lasso RO. The ethics of research biobanking. JAMA. 2010;304(8):908–10.
Malm J, Fehniger TE, Danmyr P, Vegvari A, Welinder C, Lindberg H, Appelqvist R, Sjödin K, Wieslander E, Laurell T, Hober S, Berven FS, Fenyö D, Wang X, Andrén PE, Edula G, Carlsohn E, Fuentes M, Nilsson CL, Dahlbäck M, Rezeli M, Erlinge D, Marko-Varga G. Developments in biobanking workflow standardization providing sample integrity and stability. J Proteomics. 2013;95:38–45.
Marko-Varga G. BioBanking as the central tool for translational medicine CTM issue 2013. Clin Trans Med. 2013;2(4):1–4.
Marko-Varga G, Ogiwara A, Nishimura T, Kawamura T, Fujii K, Kawakami T, Kyono Y, Tu HK, Anyoji H, Kanazawa M, Akimoto S, Hirano T, Tsuboi M, Nishio K, Hada S, Jiang H, Fukuoka M, Nakata K, Nishiwaki Y, Kunito H, Peers IS, Harbron CG, South MC, Higenbottam T, Nyberg F, Kudoh S, Kato H. Personalized medicine and proteomics: lessons from non-small cell lung cancer. J Proteome Res. 2007;6(8):2925–35.
Marko-Varga G, Vegvari A, Welinder C, Lindberg H, Rezeli M, Edula G, Svensson KJ, Belting M, Laurell T, Fehniger TE. Standardization and utilization of biobank resources in clinical protein science with examples of emerging applications. J Proteome Res. 2012;11:5124–34.
Park A. Biobanks. “Ten ideas changing the world right now.” TIME Magazine. 2009, March 9 2009.
Riegman PHJ, Morente MM, Betsou F, De Blasio P, Geary P, Marble Arch Int Working G. Biobanking for better healthcare. Mol Oncol. 2008;2(3):213–22.
Scott MG. When do new biomarkers make sense? Scand J Clin Lab Invest. 2010;70 suppl 242:90–5.
Simeon-Dubach D, Perren A. Better provenance for biobank samples. Nature. 2011;475(7357):454–5.
Taylor PJ. Matrix effects: the Achilles heel of quantitative high-performance liquid chromatography-electrospray-tandem mass spectrometry. Clin Biochem. 2005;38(4):90–5.
Vaught JB. Biorepository and biospecimen science: a new focus for CEBP. Cancer Epidemiol Biomarkers Prev. 2006;15:1572–3.
Welinder C, Jonsson G, Ingvar C, Lundgren L, Olsson H, Breslin T, Végvári A, Laurell T, Rezeli M, Jansson B, Baldetorp B, Marko-Varga G. Establishing a Southern Swedish Malignant Melanoma OMICS and biobank clinical capability. Clin Transplant Med. 2013;2(1):1326–7.
Acknowledgement and Funding
This work was supported by grants from Mrs. Berta Kamprad Foundation, Swedish Academy of Pharmaceutical Sciences, the Swedish Foundation for Strategic Research, Vinnova, Fundacion Federico SA, Ingabritt & Arne Lundbergs forskningsstiftelse and the Crafoord Foundation.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Malm, J., Marko-Varga, G. (2014). The Role of Proteomics in the Development of Personalized Medicine, Diagnostic Methods and Large Scale Biobanking. In: Marko-Varga, G. (eds) Genomics and Proteomics for Clinical Discovery and Development. Translational Bioinformatics, vol 6. Springer, Dordrecht. https://doi.org/10.1007/978-94-017-9202-8_12
Download citation
DOI: https://doi.org/10.1007/978-94-017-9202-8_12
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-017-9201-1
Online ISBN: 978-94-017-9202-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)